Work experience
Major scientific achievements of the past 10 years:
2007: Agami published 108 papers of which in 63 he acted as a corresponding last author. Of note, his top publications as senior-corresponding-last-author include: 1x Nature; 9x Cell (IF=34); 3x Nature Cell Biology; 2x Nature Biotechnology; 2x Molecular Cell; 3x Nature Communications; 3x in EMBO and 2x EMBO-Reports; 3x Genome Biology, and numerous reviews in Nature journals.
In total, his papers were cited more than 26,300, and his h-index and i10-index are 62 and 97, respectively.
2007: He was the first to demonstrate how RNA-binding proteins can potentially inhibit accessibility of microRNAs to target mRNAs (Cell).
2012: He was the first to demonstrate the identification and characterization of how an RNA-binding protein suppresses alternative polyadenylation of mRNAs and how this connects to a genetic disease
(Cell).
2013: He was the first to demonstrate how ribosome sequencing can identify disease-associated mutations in the mitochondria (Nature Communications). In the same year, we also were the first to describe that p53 is an enhancer binding protein and the enhancer RNAs are required for it function (Molecular Cell).
2016: He was the first to demonstrate how the CRISPR-Cas9 gene editing technology can be used for functional genetic screens of enhancers (Nature Biotechnology). In the same year, he was the first to show that ribosome sequencing can be used for the detection of amino acid shortages (Nature).
2017: He was the first to link transcription to mRNA translation via mRNA modifications (Cell)
2017: Follow up experiments linked lincRNAs and enhancers to cellular senescence (Genome Biology, NAR and Cancer Letters).